These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [TBL] [Abstract][Full Text] [Related]
3. Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70. Rocco B; Matei DV; de Cobelli O; Rocco F Eur Urol; 2004 Aug; 46(2):272-3; author reply 273. PubMed ID: 15245825 [No Abstract] [Full Text] [Related]
4. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S; J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055 [TBL] [Abstract][Full Text] [Related]
6. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. Di Lorenzo G; PerdonĂ S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763 [TBL] [Abstract][Full Text] [Related]
7. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342 [TBL] [Abstract][Full Text] [Related]
9. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941 [TBL] [Abstract][Full Text] [Related]
11. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794 [TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y; Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545 [TBL] [Abstract][Full Text] [Related]
13. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan. Miyake H; Sakal I; Harada K; Eto H; Hara I Hinyokika Kiyo; 2004 Mar; 50(3):151-6. PubMed ID: 15148765 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T; Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219 [TBL] [Abstract][Full Text] [Related]
18. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535 [TBL] [Abstract][Full Text] [Related]
19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719 [TBL] [Abstract][Full Text] [Related]